UAE Ministry of Health and Prevention Issues Circular to Withdraw Brilinta 90 mg Drug with Batch Number JB504 by AstraZeneca
The UAE Ministry of Health and Prevention has provided a round to all medical facilities and medical facilities to take out Brilinta 90 mg set number JB504 by AstraZeneca, with instant impact because of incorrect packaging. The medication, which is used in people with cardiac arrest and stroke, has been withdrawn since the bundle has an additional medicine called Zurampic (Lesinurad) 200mg tablet, likewise made by AstraZeneca.
H.E. Dr. Amin Hussein Al Amiri, Assistant Undersecretary for Public Health Policy and Licensing Field of the UAE Ministry of Health and Prevention, and Chairman of the Supreme National Drug Registration, stated that the US Food and Drug Administration (FDA) has actually released a warning that the maker has willingly withdrawn this set of the product. He claimed that wrong doses of Zurampic could result in renal failure, while abrupt discontinuation of Brilinta could raise the threat of cardiac arrest and stroke. He included that Brilinta has been authorized by the FDA for the prevention of preventing blood clotting to lower events of cardiovascular death and cardiovascular disease in patients with acute coronary syndrome (A/C).
The UAE Ministry of Health and Prevention is in contact with worldwide pharmaceutical companies to circulate any type of caution.
The Assistant Undersecretary clarified that Zurampic is not signed up in the Ministry's Medicine Department; nonetheless, to make sure the safety of individuals, it has been determined to release the round and take the necessary action.
H.E. Dr. Al Amiri stressed that the Ministry remains in routine contact with the FDA and the medicine authorities of Europe and Australia. He stated that if any warning is released pertaining to any kind of medicine, the Ministry promptly takes action and issues a circular to all concerned health authorities to remove these products and destroy them, making certain health and safety of the community.
The public is requested to inform the Ministry of Health and Prevention in case of any side effects from a drug.
If you experience any medicine related side effects, please fill in the ADR Side Results Form which could be downloaded from http://www.cpd-pharma.ae, or contact pv@moh.gov.ae, or get in touch with 971023201448 or fax on 971023201947.
